CA2378898A1 - Procede de mesure de l'activite du facteur coagulant - Google Patents

Procede de mesure de l'activite du facteur coagulant Download PDF

Info

Publication number
CA2378898A1
CA2378898A1 CA002378898A CA2378898A CA2378898A1 CA 2378898 A1 CA2378898 A1 CA 2378898A1 CA 002378898 A CA002378898 A CA 002378898A CA 2378898 A CA2378898 A CA 2378898A CA 2378898 A1 CA2378898 A1 CA 2378898A1
Authority
CA
Canada
Prior art keywords
inhibitor
whole blood
blood
sample
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002378898A
Other languages
English (en)
Inventor
Nigel Mackman
John J. Mcdonnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COAGULATION DIAGNOSTICS Inc
Scripps Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2378898A1 publication Critical patent/CA2378898A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des procédés d'évaluation rapide des propriétés coagulantes globales d'un échantillon sanguin d'un patient, qui consistent à mesurer et à comparer le temps de coagulation avec et sans inhibiteur ajouté d'un procoagulant ou d'un anticoagulant. Lorsque l'échantillon est constitué de sang entier, le temps de coagulation résultant représente l'activité coagulante globale du plasma et des composants cellulaires du sang, laquelle est représentative d'une pathologie existante ou imminente découlant d'une coagulabilité anormale. L'invention porte également sur un procédé de mesure du risque chez un patient d'événement thrombotique, par la détermination des taux courants au plan fonctionnel de procoagulant(s) ou d'anticoagulant(s) dans le sans entier. Par ailleurs, une méthode de mesure de l'efficacité d'une thérapie anticoagulante est décrite ainsi que des kits pour la mise en oeuvre de la méthode de l'invention.
CA002378898A 1999-07-23 2000-07-24 Procede de mesure de l'activite du facteur coagulant Abandoned CA2378898A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14514099P 1999-07-23 1999-07-23
US60/145,140 1999-07-23
PCT/US2000/020118 WO2001007070A1 (fr) 1999-07-23 2000-07-24 Procede de mesure de l'activite du facteur coagulant

Publications (1)

Publication Number Publication Date
CA2378898A1 true CA2378898A1 (fr) 2001-02-01

Family

ID=22511767

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002378898A Abandoned CA2378898A1 (fr) 1999-07-23 2000-07-24 Procede de mesure de l'activite du facteur coagulant

Country Status (7)

Country Link
EP (1) EP1212073A4 (fr)
JP (1) JP2003505678A (fr)
KR (1) KR20020042622A (fr)
CN (1) CN1368886A (fr)
AU (1) AU6369700A (fr)
CA (1) CA2378898A1 (fr)
WO (1) WO2001007070A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743596B1 (en) * 2000-10-27 2004-06-01 Biomerieux, Inc. Method of determining global coagulability hemostatic potential
US20030064414A1 (en) * 2001-03-30 2003-04-03 Benecky Michael J. Rapid assessment of coagulation activity in whole blood
DE102005005824A1 (de) * 2005-02-08 2006-08-17 Zlb Behring Gmbh Methode zur Differenzierung von Faktor XIII-gegenüber Fibrinogen-Mangelzuständen unter Einsatz thrombelastographischer Techniken
JP4267592B2 (ja) * 2005-05-23 2009-05-27 潤 川崎 抗血栓薬薬効試験法
CN100434901C (zh) * 2006-01-12 2008-11-19 上海交通大学 血红蛋白凝胶层析的教学试剂盒
CA2641189A1 (fr) * 2006-01-31 2007-08-09 Mitsubishi Kagaku Iatron, Inc. Procede pour determiner l'etat d'un syndrome de coagulation intravasculaire disseminee
GB0701821D0 (en) * 2007-02-01 2007-03-14 Pentapharm Ag Diagnostic composition and its use in the determination of coagulation characteristics of a test liquid
US8574849B2 (en) 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
JP5739816B2 (ja) 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉインヒビターおよび使用法
NZ603028A (en) 2010-03-19 2014-11-28 Baxter Healthcare Sa Tfpi inhibitors and methods of use
EP2471945A1 (fr) * 2010-12-30 2012-07-04 Siemens Healthcare Diagnostics Products GmbH Procédé de détermination d'inhibiteurs de coagulation
KR102263685B1 (ko) 2012-03-21 2021-06-11 다케다 야쿠힌 고교 가부시키가이샤 Tfpi 저해제 및 사용 방법
US20150278470A1 (en) * 2012-10-25 2015-10-01 Koninklijke Philips N.V. Combined use of clinical risk factors and molecular markers fro thrombosis for clinical decision support
EP3470837A1 (fr) 2013-01-20 2019-04-17 Dyax Corp. Traitement de troubles dans lesquels intervient pkal
EP2818871A1 (fr) 2013-06-28 2014-12-31 Roche Diagniostics GmbH Moyens et procédés pour étalonnage universel de tests anti-facteur Xa
CN103604766A (zh) * 2013-11-25 2014-02-26 牡丹江友搏药业股份有限公司 一种疏血通注射液的生物学质控方法
US9452199B2 (en) * 2014-01-17 2016-09-27 General Electric Company Platelet activation and growth factor release using electric pulses
SE540132C2 (sv) * 2014-05-22 2018-04-10 Zafena Ab Analysmetod för bestämning av antikoagulanter i blod eller blodplasma
CN104345154B (zh) * 2014-08-22 2016-10-26 北京蛋白质组研究中心 一种检测多肿瘤相关“多肽-蛋白组合式标志物”的双抗体夹心试剂盒
CN104177503B (zh) * 2014-08-22 2018-04-13 北京蛋白质组研究中心 一种激酶通路相关“多肽‑蛋白组合式”标志物及定量检测技术
CN104698159B (zh) * 2015-03-10 2017-03-08 中国科学院苏州生物医学工程技术研究所 一种内毒素含量的检测方法
CN110192105B (zh) * 2017-01-06 2022-04-12 索尼公司 凝血系统分析和失血量预测装置、系统、方法和程序
US20210263052A1 (en) * 2018-07-25 2021-08-26 Sony Corporation Blood coagulation system analysis device
WO2020190266A1 (fr) * 2019-03-15 2020-09-24 Coagulation Sciences Llc Dispositif de test de coagulation, système et procédé d'utilisation
US10429377B1 (en) 2019-03-15 2019-10-01 Coagulation Sciences Llc Coagulation test device, system, and method of use
KR20210153097A (ko) 2019-04-16 2021-12-16 다케다 파머수티컬 컴패니 리미티드 기능성 c1 에스테라제 저해제(fc1-inh)의 정량 방법
RU2750839C1 (ru) * 2020-05-18 2021-07-05 Общество с ограниченной ответственностью "Меднорд-Техника" (ООО "Меднорд-Т") Устройство и способ экспресс-оценки агрегационной активности форменных элементов крови
JPWO2022145475A1 (fr) * 2020-12-28 2022-07-07

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814247A (en) * 1983-01-26 1989-03-21 University Of Medicine And Dentistry Of New Jersey Method for determining the existance and/or the monitoring of a pathological condition in a mammal
US4882272A (en) * 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
US5783447A (en) * 1996-10-02 1998-07-21 University Of Medicine And Dentistry Of New Jersey Hypercoagulability comparative determinants obtained using detection systems with variable force-induced energy inputs
EP1084270B1 (fr) * 1998-06-08 2004-08-25 The University Of Vermont And State Agricultural College Méthode de mesure de la coagulation dans le plasma

Also Published As

Publication number Publication date
EP1212073A1 (fr) 2002-06-12
WO2001007070A1 (fr) 2001-02-01
EP1212073A4 (fr) 2003-09-03
KR20020042622A (ko) 2002-06-05
JP2003505678A (ja) 2003-02-12
CN1368886A (zh) 2002-09-11
AU6369700A (en) 2001-02-13

Similar Documents

Publication Publication Date Title
CA2378898A1 (fr) Procede de mesure de l'activite du facteur coagulant
Lowe et al. Plasma fibrinogen
US5525477A (en) Method for diagnosing blood clotting disorders
US20030064414A1 (en) Rapid assessment of coagulation activity in whole blood
Brummel‐Ziedins et al. Thrombin generation: phenotypic quantitation
US6245573B1 (en) Rapid assessment of the coagulant activity of blood
Lippi et al. Milestones and perspectives in coagulation and hemostasis
US5525478A (en) Soluble thrombomodulin-based one-stage assay for vitamin-K dependent coagulation-inhibiting proteins
EP2235542B1 (fr) Procédé in vitro de diagnostic pour évaluer la maladie de von willebrand et le risque saignement associé avec la maladie de von willebrand et les troubles acquis ou congénitaux de fonction plaquettaire
Simpson et al. Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults
CA2623142A1 (fr) Methodes de test global de la coagulation et de la fibrinolyse
JP3248621B2 (ja) 血栓症リスクのテスト
CA2155503C (fr) Methode de detection des anomalies de coagulation sanguine a mediation proteique/proteique
Hoffmann et al. Automated nephelometry of fibrinogen: analytical performance and observations during thrombolytic therapy.
Laffan et al. 17 Investigation of a thrombotic tendency
Cellai et al. Assessment of fibrinolytic activity by measuring the lysis time of a tissue factor-induced clot: a feasibility evaluation
Ruberto et al. Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk.
Fritsma 42 Laboratory Evaluation of Hemostasis
JP2007503589A (ja) 活性化混合物
Fekete et al. Laboratory modalities for assessing hemostasis during cardiopulmonary bypass
Kato et al. Differences in the composition of activated partial thromboplastin time (APTT) reagents affect clot waveform analysis
US11630101B2 (en) Method for diagnosing anomalies in the coagulation of blood
Ibbotson et al. Thrombin generation and factor VIII: C levels in patients with type 1 diabetes complicated by nephropathy
De Metz et al. Use of a centrifugal analyzer for a chromogenic prothrombin time, a chromogenic activated partial thromboplastin time and a kinetic fibrinogen assay in a routine hospital laboratory
Herskovits et al. Comparison of Russell viper venom–based and activated partial thromboplastin time–based screening assays for resistance to activated protein C

Legal Events

Date Code Title Description
FZDE Dead